Marker Therapeutics Reports Q1 2022 Operating and Financial Results
Topline readout of Phase 2 AML trial Group 2 active disease anticipated in Q2 2022
Company plans to file INDs in lymphoma and pancreatic cancer by year end, with clinical trials to be initiated in 2023
“2022 has already been an exciting year for Marker as we reported encouraging initial results from the six-patient safety lead-in portion of our Phase 2 AML trial—including elimination of MRD in one MRD positive patient—and announced plans for Company-sponsored trials of our second cell therapy product candidate, MT-601, in pancreatic cancer and lymphoma,” said Peter
PROGRAM UPDATES AND EXPECTED MILESTONES
Acute Myeloid Leukemia (MT-401)
- In February 2022, Marker announced the initial results of the safety lead-in stage of its Company-sponsored Phase 2 AML trial evaluating MT-401, Marker’s lead MultiTAA-specific T cell product candidate. Results from the safety lead-in demonstrate that MT-401 was well-tolerated, eliminated measurable residual disease (MRD) based on peripheral blood analysis at Week 32 in one MRD positive patient and induced epitope spreading across multiple AML-associated antigens in that patient.
- Enrollment of the first 20 patients of the main Phase 2 stage of the AML trial was completed in Q4 2021. Topline readout of Group 2 active disease is anticipated in Q2 2022.
- Marker announced in February 2022 that it is developing MT-401-
OTS , a scalable, off-the-shelf product candidate with the potential to match patients to treatment in under three days. Marker’s open Investigational New Drug application (IND) for MT-401 for the treatment of AML includes an off-the-shelf program. The Company is in the process of developing a patient cell bank inventory and expects to dose the first patient with MT-401-OTS 2023.
Additional Clinical Programs (MT-601)
- In January 2022, Marker announced that the U.S. Food and Drug Administration granted Orphan Drug designation to MT-601 for the treatment of pancreatic cancer.
- Marker announced in
February 2022 that the Company intends to file INDs for MT-601, Marker’s second MultiTAA-specific T cell product candidate, in lymphoma and pancreatic cancer in 2022. The Company expects to initiate these trials in 2023.
BUSINESS UPDATES
- In
April 2022 , the Company announced that it entered into a services agreement withWilson Wolf Manufacturing Corporation . The agreement includes an$8.0 million upfront cash payment by Wilson Wolf to Marker in exchange for services relating to Marker’s expertise in the manufacture of cell therapies. Wilson Wolf has agreed to pay Marker an additional$1.0 million if the certain work, as defined in the services agreement, is completed within one year from the onset of the services agreement.
FIRST QUARTER 2022 FINANCIAL RESULTS
Cash Position and Guidance: At
R&D Expenses: Research and development expenses were
G&A Expenses: General and administrative expenses were
Net Loss: Marker reported a net loss of
About
To receive future press releases via email, please visit: https://www.markertherapeutics.com/email-alerts.
Forward-Looking Statements
This release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company’s expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: our research, development and regulatory activities and expectations relating to our non-engineered multi-tumor antigen specific T cell therapies; the effectiveness of these programs or the possible range of application and potential curative effects and safety in the treatment of diseases; the timing, conduct and success of our clinical trials, including the Phase 2 trial of MT-401; our ability to use our manufacturing facilities to support clinical and commercial demand; the timing and use of the CPRIT award; and our future operating expenses and capital expenditure requirements. Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stated in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the Company’s most recent Form 10-K, 10-Q and other
Condensed Consolidated Balance Sheets (Unaudited) |
||||||||
| 2022 | 2021 | |||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 28,637,217 | $ | 42,351,145 | ||||
| Restricted cash | 181,864 | 1,146,186 | ||||||
| Prepaid expenses and deposits | 2,196,225 | 2,484,634 | ||||||
| Other receivables | 2,185 | 237 | ||||||
| Total current assets | 31,017,491 | 45,982,202 | ||||||
| Non-current assets: | ||||||||
| Property, plant and equipment, net | 10,276,936 | 10,096,861 | ||||||
| Construction in progress | 4,089,135 | 2,225,610 | ||||||
| Right-of-use assets, net | 9,572,572 | 9,830,461 | ||||||
| Total non-current assets | 23,938,643 | 22,152,932 | ||||||
| Total assets | $ | 54,956,134 | $ | 68,135,134 | ||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
| Current liabilities: | ||||||||
| Accounts payable and accrued liabilities | $ | 7,348,680 | $ | 11,134,913 | ||||
| Lease liability | 683,969 | 620,490 | ||||||
| Deferred revenue | 181,864 | 1,146,186 | ||||||
| Total current liabilities | 8,214,513 | 12,901,589 | ||||||
| Non-current liabilities: | ||||||||
| Lease liability, net of current portion | 11,035,857 | 11,247,950 | ||||||
| Total non-current liabilities | 11,035,857 | 11,247,950 | ||||||
| Total liabilities | 19,250,370 | 24,149,539 | ||||||
| Stockholders' equity: | ||||||||
| Preferred stock - |
- | - | ||||||
| Common stock, |
83,451 | 83,079 | ||||||
| Additional paid-in capital | 443,651,176 | 442,020,871 | ||||||
| Accumulated deficit | (408,028,863 | ) | (398,118,355 | ) | ||||
| Total stockholders' equity | 35,705,764 | 43,985,595 | ||||||
| Total liabilities and stockholders' equity | $ | 54,956,134 | $ | 68,135,134 | ||||
Condensed Consolidated Statements of Operations (Unaudited) |
||||||||
| For the Three Months Ended | ||||||||
| 2022 | 2021 | |||||||
| Revenues: | ||||||||
| Grant income | $ | 964,322 | $ | - | ||||
| Total revenues | 964,322 | - | ||||||
| Operating expenses: | ||||||||
| Research and development | $ | 7,026,066 | $ | 5,643,029 | ||||
| General and administrative | 3,733,001 | 3,137,958 | ||||||
| Total operating expenses | 10,759,067 | 8,780,987 | ||||||
| Loss from operations | (9,794,745 | ) | (8,780,987 | ) | ||||
| Other income (expenses): | ||||||||
| Arbitration settlement | (118,880 | ) | - | |||||
| Interest income | 3,117 | 1,537 | ||||||
| Net loss | $ | (9,910,508 | ) | $ | (8,779,450 | ) | ||
| Net loss per share, basic and diluted | $ | (0.12 | ) | $ | (0.16 | ) | ||
| Weighted average number of common shares outstanding, basic and diluted | 83,107,649 | 56,470,247 | ||||||
Condensed Consolidated Statements of Cash Flows (Unaudited) |
||||||||
| For the Three Months Ended | ||||||||
| 2022 | 2021 | |||||||
| Cash Flows from Operating Activities: | ||||||||
| Net loss | $ | (9,910,508 | ) | $ | (8,779,450 | ) | ||
| Reconciliation of net loss to net cash used in operating activities: | ||||||||
| Depreciation and amortization | 576,331 | 502,743 | ||||||
| Stock-based compensation | 1,630,677 | 1,377,038 | ||||||
| Amortization of right-of-use assets | 257,889 | 251,626 | ||||||
| Changes in operating assets and liabilities: | ||||||||
| Prepaid expenses and deposits | 288,409 | 95,000 | ||||||
| Other receivables | (1,948 | ) | (308 | ) | ||||
| Accounts payable and accrued expenses | (3,953,976 | ) | (1,482,473 | ) | ||||
| Deferred revenue | (964,322 | ) | - | |||||
| Lease liability | (148,614 | ) | (64,329 | ) | ||||
| Net cash used in operating activities | (12,226,062 | ) | (8,100,153 | ) | ||||
| Cash Flows from Investing Activities: | ||||||||
| Purchase of property and equipment | (826,583 | ) | (442,277 | ) | ||||
| Cash used for construction in progress | (1,625,605 | ) | (958,965 | ) | ||||
| Net cash used in investing activities | (2,452,188 | ) | (1,401,242 | ) | ||||
| Cash Flows from Financing Activities: | ||||||||
| Proceeds from issuance of common stock, net | - | 52,656,588 | ||||||
| Net cash provided by financing activities | - | 52,656,588 | ||||||
| Net (decrease) increase in cash, cash equivlants and restricted cash | (14,678,250 | ) | 43,155,193 | |||||
| Cash, cash equivalents and restricted cash at beginning of the period | 43,497,331 | 21,352,382 | ||||||
| Cash, cash equivalents and restricted cash at end of the period | $ | 28,819,081 | $ | 64,507,575 | ||||
Investors and Media Contacts
Vice President/Head of Investor Relations, PR & Marketing
(713) 400-6451
Investor.Relations@markertherapeutics.com
Solebury Trout:
Media
Abonanno@soleburytrout.com
Source: Marker Therapeutics